Shots:

• The P-III MINISTONE-2 (NCT03629184) study involves assessing of Xofluza vs Oseltamivir in children with an influenza infection aged b\w 1 to ≤12yrs. confirmed by rapid influenza diagnostic test/ influenza symptoms
• The P-III MINISTONE-2 study resulted in meeting its 1EPs demonstrating reduction in duration of flu symptoms including fever and is well tolerated in children with flu
• Xofluza is an oral therapy approved in the US & Japan in treating influenza in children- being evaluated in P-III MINISTONE-1 study for flu in children < 1yr. with its expected FDA’s sNDA approval on Nov 04- 2019

Click here to read full press release/ article | Ref: Genentech | Image: Commercial Cafe